Abstract
Vascular calcification, both in the coronary and in the peripheral arteries, is associated with increased cardiovascular (CV) risk. However, agents that prevent vascular calcification (e.g. estrogens or calcimimetic agents) might have neutral or detrimental effects on CV events. Moreover, statins and antihypertensive agents do not appear to modify vascular calcification, despite their established benefits on CV disease prevention. On the other hand, recent data suggest that microRNAs play a role in the regulation of vascular calcification. It is therefore possible that modulation of the expression of microRNAs might represent a useful strategy for preventing or delaying the progression of this process.
Keywords: Vascular calcification, cardiovascular risk, microRNA, statins, coronary artery calcium, aortic stenosis.
Current Vascular Pharmacology
Title:Editorial: Vascular Calcification, Cardiovascular Risk and microRNAs
Volume: 14 Issue: 2
Author(s): Konstantinos Tziomalos, Vasilios G. Athyros and Asterios Karagiannis
Affiliation:
Keywords: Vascular calcification, cardiovascular risk, microRNA, statins, coronary artery calcium, aortic stenosis.
Abstract: Vascular calcification, both in the coronary and in the peripheral arteries, is associated with increased cardiovascular (CV) risk. However, agents that prevent vascular calcification (e.g. estrogens or calcimimetic agents) might have neutral or detrimental effects on CV events. Moreover, statins and antihypertensive agents do not appear to modify vascular calcification, despite their established benefits on CV disease prevention. On the other hand, recent data suggest that microRNAs play a role in the regulation of vascular calcification. It is therefore possible that modulation of the expression of microRNAs might represent a useful strategy for preventing or delaying the progression of this process.
Export Options
About this article
Cite this article as:
Tziomalos Konstantinos, Athyros G. Vasilios and Karagiannis Asterios, Editorial: Vascular Calcification, Cardiovascular Risk and microRNAs, Current Vascular Pharmacology 2016; 14 (2) . https://dx.doi.org/10.2174/157016111402160208150816
DOI https://dx.doi.org/10.2174/157016111402160208150816 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Atrial Fibrillation and Chronic Kidney Disease in Hypertension: A Common and Dangerous Triad
Current Vascular Pharmacology Chemistry and Applications of 4-Hydroxyquinolin-2-one and Quinoline-2,4-dionebased Compounds
Current Organic Chemistry Fish Hydrolysates: A Regulatory Perspective of Bioactive Peptides
Protein & Peptide Letters Cardioprotective Properties of HDL: Structural and Functional Considerations
Current Medicinal Chemistry Emerging Anticoagulant Therapies for Atrial Fibrillation: New Options, New Challenges
Current Medicinal Chemistry Aging and DNA Methylation
Current Chemical Biology HDL Dysfunction Caused by Mutations in apoA-I and Other Genes that are Critical for HDL Biogenesis and Remodeling
Current Medicinal Chemistry Updated Electrocardiographic Classification of Acute Coronary Syndromes
Current Cardiology Reviews Ghrelin as a Potential Anti-Obesity Target
Current Pharmaceutical Design The GH/IGF-1 Axis in Chronic Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets Polyphenols: A Diverse Class of Multi-Target Anti-HIV-1 Agents
Current Drug Metabolism New Class of Pyrimidinesulfamoyl Containing Pyrazole and Pyrrole Derivatives and Their Antioxidant Activity
Letters in Organic Chemistry A Review of IGF1 Signaling and IGF1-related Long Noncoding RNAs in Chemoresistance of Cancer
Current Cancer Drug Targets A Comprehensive Review on Recent Developments in the Field of Biological Applications of Potent Pyrazolines Derived from Chalcone Precursors
Letters in Drug Design & Discovery Familial Hypercholesterolemia: Update and Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial [Hot Topic:Structuring Chemical Information for Quicker and More Reliable Drug Safety Assessment (Guest Editor: Romualdo Benigni)]
Current Computer-Aided Drug Design Advances in Antiplatelet Therapy for Stroke Prevention: the New P2Y12 antagonists
Current Drug Targets Antiplatelet Treatment in Stroke: New Insights
Current Pharmaceutical Design Assessing Depression in Patients with an Acute Coronary Syndrome: A Literature Review
Current Psychiatry Reviews Fishing for Age-Related Visual System Mutants: Behavioral Screening of Retinal Degeneration Genes in Zebrafish
Current Aging Science